Individual cells are the foundation of the human body. How cells work together defines who we are, how we function and the diseases we have. Now, for the first time, we are able to see how individual cells interact at a level of resolution that was not previously possible.
We are on a quest to leverage the power of single-cell RNA sequencing to discover precision therapeutics for complex diseases such as autoimmunity and cancer. These diseases are comprised of many different cells, making them difficult to understand and to treat effectively. Combining massive datasets of unprecedented complexity and sophisticated machine learning algorithms allows us to understand the specific cells, among many others, that are causing the disease, and to identify the genes that are triggering their malfunction. With this new level of clarity, this approach has the unique potential to deliver a powerful new class of medicines and make a meaningful difference for patients.
Product engineConstantly exploring new ideas and perspectives that motivate us to never stop innovating and making meaningful discoveries
Bringing our community together to create strong, collaborative relationships in an ecosystem that inspires us to work tirelessly to make a difference
Fiercely committed to responsibly executing with speed and excellence to bring transformative therapies to patients in need
September 23
Cambridge, MA – September 23, 2019 – Celsius Therapeutics, a company focused on bringing personalized medicine to patients with cancer, autoimmunity and other complex diseases, today announced that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the […]
September 19
Celsius Applying its Single-Cell Genomics Platform Across Multiple Tumor Types and Immuno-Oncology Clinical Trials CAMBRIDGE, Mass., September 19, 2019 – Celsius Therapeutics, a company focused on bringing personalized medicine to patients with cancer, autoimmunity and other complex diseases, today announced the signing of collaboration agreements with the Parker Institute for Cancer Immunotherapy (San Francisco, USA), Institut […]
You are now leaving Celsius Therapeutics to visit a third-party website, which is solely responsible for all content and privacy policies.
